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Abstract
A prominent clinical symptom in multiple sclerosis (MS), a progressive disorder of the central nervous system (CNS) due to
heightened neuro-inflammation, is learning and memory dysfunction. Here, we investigated the effects of a ketogenic diet
(KD) on memory impairment and CNS-inflammation in a murine model of experimental autoimmune encephalomyelitis
(EAE), using electrophysiological, behavioral, biochemical and in vivo imaging approaches. Behavioral spatial learning
deficits were associated with motor disability in EAE mice, and were observed concurrently with brain inflammation. The KD
improved motor disability in the EAE model, as well as CA1 hippocampal synaptic plasticity (long-term potentiation) and
spatial learning and memory (assessed with the Morris Water Maze). Moreover, hippocampal atrophy and periventricular
lesions in EAE mice were reversed in KD-treated EAE mice. Finally, we found that the increased expression of inflammatory
cytokines and chemokines, as well as the production of reactive oxygen species (ROS), in our EAE model were both
suppressed by the KD. Collectively, our findings indicate that brain inflammation in EAE mice is associated with impaired
spatial learning and memory function, and that KD treatment can exert protective effects, likely via attenuation of the
robust immune response and increased oxidative stress seen in these animals.
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Introduction
Clinical symptoms in multiple sclerosis (MS), an autoimmune
inflammatory disorder of the central nervous system (CNS), not
only include motor disability but also cognitive deficits. Cognitive
impairments are primarily learning and memory difficulties in
43% to 70% of MS patients during both early and late stages of
MS [1]. Recent brain magnetic resonance imaging (MRI) studies
in patients with MS have shown structural derangements of both
the cerebral cortex and the hippocampus (a primary locus of
memory consolidation). Moreover, convincing evidence of mem-
ory dysfunction in MS patients has been reported [2–4].
Experimentalautoimmuneencephalomyelitis(EAE),acommon-
ly employed animal model of MS – characterized by inflammation
and neurodegeneration in the CNS – has been shown to
recapitulate hippocampal injury and synaptic loss with resultant
impairment in spatial learning and memory [5]. Indeed, the extent
of memory decline, more than the degree of motor disability, has
proven to be a significant predictor of social handicap in MS [6].
One of the hallmark features of MS/EAE is immune-mediated
CNS inflammation [7,8], which subsequently facilitates reactive
oxygen species (ROS) generation in a feed-back manner [9,10].
Intriguingly, it has been observed that learning and memory
decline in models of Alzheimer’s disease and normal rodents is
accompanied by a cytokine burst [11–13], whereas cytokine
blockade prevents such cognitive impairment [11,13]. Further, it is
known that ROS generation that exceeds cellular antioxidant
capacity leads to disruption of hippocampal synaptic plasticity
[14]. Despite the growing literature supporting the critical
pathogenic role of inflammatory cytokines and chemokines, and
aberrant ROS production in EAE/MS, it is unknown whether
these factors are directly involved in contribution to memory loss
in both humans and in the EAE model.
Dietary treatments have rapidly emerged as an alternative
intervention for a variety of neurological disorders. Specially, the
ketogenic diet (KD) has been shown to be clinically efficacious and
safe in patients with medically refractory epilepsy [15]. The broad
neuroprotective properties of the KD have been highlighted in
a growing number of experimental models. For example, the KD
attenuated amyloid beta 40 and 42 deposition in a mouse model of
Alzheimer’s disease [16] and restored motor deficits in transgenic
amyotrophic lateral sclerosis (ALS) mice [17]. Additionally, either
inflammation or thermal nociception was significantly attenuated
by KD treatment [18]. While the mechanisms underlying such
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ROS production by increasing the expression and activity of
mitochondrial uncoupling proteins [19].
In the present study, we asked whether inflammatory responses
and oxidative stress in a murine model of EAE are linked to
memory dysfunction in mice. We found that impairment of spatial
learning and memory in vivo and synaptic plasticity in vitro
correlated closely with increased cytokine/chemokine expression
and ROS generation. Further, we observed that the KD
significantly dampened motor disability, CNS inflammation and
memory dysfunction in EAE mice, suggesting that dietary
interventions may prove to be clinically useful in the treatment
of MS.
Methods
EAE Induction
C57BL/6 (B6) mice purchased from Taconic Farms were
housed in an animal facility. The mice were 6–8 wk of age at the
beginning of the study, and both standard and KD were given ad
lib. EAE was induced by subcutaneous injection of myelin
oligodendrocyte glycoprotein (MOG)35–55 peptide emulsified with
complete Freund’s adjuvant (CFA) containing 500 mg of non-
viable Mycobacterium tuberculosis, followed by intravenous injection of
20 ng of pertussis toxin in C57BL/6 (B6) mice. After EAE
induction, the change in motor function was monitored daily using
an arbitrary scale: 0, no symptoms; 1, flaccid tail; 2, hindlimb
weakness or abnormal gait; 3, complete hindlimb paralysis; 4,
complete hindlimb paralysis with forelimb weakness or paralysis;
5, moribund or deceased. The KD (Bio-Serv F3666 diet,
Frenchtown, NJ, USA; 6.3:1 ratio of fats: carbohydrate+protein)
was fed to a separate cohort of mice 7 days before EAE induction
and was continued until the time of sacrifice. All animal handling
protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at the Barrow Neurological Institute and St.
Joseph’s Hospital & Medical Center (Protocol Number 0277).
Magnetic Resonance Imaging (MRI)
Cerebral imaging was performed on a 7 T rodent MRI scanner
using a 20 mm RF-Quadrature-Volume head coil. Axial and
coronal T1-weighted (MSME; TE 10.5 ms, TR 322 ms, 0.5 mm
slice thickness, matrix 2566256, field of view [FOV] 2.8 cm, eight
averages, 40 coronal slices, scan time 22 minutes, and 20 axial
slices, scan time 16 min), fat-suppressed turbo spin echo T2-
weighted (RARE; TE1 14.5 ms, TE2 65.5 ms, TR 4500 ms,
0.5 mm slice thickness, Matrix 2566256, FOV 2.8 cm, eight
averages, 40 coronal slices, scan time 28 minutes, and 20 axial
slices, scan time 28 minutes) MRI data were analyzed using the
MEDx3.4.3 software package (Medical Numerics, VA, USA) on
a LINUX workstation.
Morris Water Maze Testing
Spatial learning and memory were assessed using the standard
Morris water maze (MWM), consisting of a circular tank
(diameter, 56 in) filled with opaque water by the addition of
non-toxic white paint (Fresco Powder tempera, Northvale, NJ) and
a hidden platform in a fixed spot. Visual cues were placed in each
of the four arbitrarily defined quadrants of the tank. During 5 days
of initial training, the mice were dropped in the water maze in one
of the four equal quadrants labeled north, east, south and west.
Their order of use was changed daily. The mice were given four
90-second training trials per day. Regardless of success or failure to
reach the hidden platform, all mice were given an additional 30-
sec on the platform and then placed in its heated cage until its next
trial. After initial training, the mice were placed in the tank and
allowed to swim for 90 seconds to search for the submerged
platform (4 daily trials over 5 consecutive days). The path lengths
and latencies to platform discovery were measured using the
EthoVision XT video tracking system (Noldus Information
Technology, Leesburg, VA, USA).
Electrophysiology
Based on changes in motor disability after EAE induction, the
alteration of long-term potentiation was tested at two time-points
(e.g., peak and mild disability). To address this, transverse
hippocampal slices (400 mm) were prepared from brains of three
groups of mice [control mice (naı ¨ve), standard diet (SD)-fed EAE
and ketogenic diet (KD)-fed EAE] using a standard vibratome
(The Vibratome Company, St. Louis, MO, USA) at either post-
natal days 14–19 or 31–40. Slices were stored in oxygenated
physiological saline (composition in mM: 124 NaCl, 1.8 MgSO4,
4 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2.4 CaCl2, and 10 D-
glucose; pH=7.4) prior to recording. Each slice was then
transferred to a recording chamber attached to an Axioskop FS2
microscope (Carl Zeiss Microimaging, Inc., Thornwood, NY,
USA) and superfused with warm (3461uC) physiological saline at
a rate of 2–3 ml/min before the start of each experiment. Upon
Schaffer collateral (SC) stimulation, excitatory postsynaptic
potentials (EPSPs) were recorded at a control test frequency of
0.05 Hz (0.1 ms, 20–100 mA) from CA1 stratum radiatum. After
establishing a standard input-output curve (i.e., stimulus intensity
vs. EPSP amplitude), the baseline EPSP amplitude (over 1 mV)
was set to 50% of maximum responses. High-frequency stimula-
tion (HFS, 1 sec, 100 Hz) or theta-burst stimuli (TBS, consisting of
5 trains delivered at 0.2 Hz) were used to induce long-term
potentiation (LTP, an electrophysiological measure of memory
consolidation). LTP was expressed as the percent of the mean
baseline EPSP amplitude during 5–10 min without HFS. We also
used TBS-induced LTP to confirm the changes in synaptic
plasticity seen with HFS. Recorded data were filtered at 3 kHz,
sampled at 10 kHz using pClamp, and analyzed with Clampfit
(Axon Instruments, Union City, CA, USA). Chemicals used in
electrophysiological study were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
CNS Cell Isolation and Flow Cytometry
To purify CNS cells, mice were transcardially perfused with
phosphate buffer saline (PBS). Mononuclear T cells were collected
from the brains of 5 mice using Percoll density gradients (30-70%).
Single cell suspensions (4610
5 cells) were prepared and stained for
cell surface markers of the following antigens (targeted by the
indicated Antibody (Ab) fluorescently tagged with FITC, PE,
allophycocyanin, PE-Cy5, or PE-Cy7): CD3, CD4, CD8, CD11b,
CD19 and CD45. All Abs were purchased from BD Pharmingen.
FACS analysis was performed on a FACSAria
TM system using
Diva software (BD Biosciences, CA, USA).
Measurement of Cytokines and Chemokines
Both brain and spinal cord tissues were homogenized with PBS
mixed with Halt protease inhibitor. After sonication, samples were
centrifuged at 4uC for 20 min at 13,000 rpm. Isolated super-
natants were mixed with a cocktail of reagents from a multi-
cytokine and chemokine assay kit (Multi-Analyte ELISArray Kit;
SA biosciences, USA) following the manufacturer’s instructions.
Optical density was measured at 450 nm wavelength using
a microplate reader (BioRad Model 680, Hercules, CA, USA).
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To evaluate the magnitude of CNS ROS changes in vivo after
EAE induction with and without KD treatment, dihydroethidium
(DHE, 10 mg/ml, Molecular Probes, Eugene, OR, USA) was
dissolved in DMSO and injected intraperitoneally at a dose of
27 mg/kg. Mice were anesthetized with an initial dose of 5%
isoflurane, followed by a maintenance dose of 2.5% isoflurane,
during bioluminescent imaging of the live mice which was
conducted over a 1 min acquisition times using an in vivo imaging
system (Xenogen IVIS Spectrum, Caliper Life Sciences, Hopkin-
ton, MA, USA). Signal intensities from the brain were defined and
measured in the efficiency mode with the Xenogen system.
Statistics
Numerical data were expressed as the mean 6 SEM. The
Mann-Whitney U test, student’s t-test and one-way ANOVA
followed by Tukey test were used to assess differences and variance
amongst different experimental groups. Significance was set at
p,0.05.
Results
The Ketogenic Diet Ameliorates Motor Disability and
Cognitive Impairment in EAE Mice
Consistent with a previous clinical report indicating that sub-
clinical memory impairment is not associated with motor disability
in benign MS patients [20], we found a lack of motor dysfunction
and visible brain MRI changes after immunization but prior to
evidence of EAE onset. However, the progressive decline in spatial
learning and memory function correlated inversely with ROS
levels in the brain of EAE mice (Figure 1). EAE mice exhibited
monophasic neurological symptoms of acute disseminated en-
cephalomyelitis 10 days following immunization (Figure 2A).
Using our previously reported motor disability scale, where higher
numbers reflect greater impairment [21], the mean clinical score
was 2.860.37 at 17 days post EAE induction and remained stable
thereafter (at about 1.2) 20 days post EAE. In KD-fed EAE mice,
disability at both the peak stage (14–19 days) and mild recovery
stage (25–35 days) was significantly decreased compared to SD-fed
EAE mice (p,0.01); the clinical score measured 1.960.2 and
0.3960.1 at 17 days and 30 days post EAE, respectively
(Figure 2A).
During the initial immunization period before EAE onset, KD
treatment prevented a decline in behavioral spatial learning and
memory (Figure 2B). No significant differences were found
between the latencies of SD-fed naı ¨ve mice and KD-fed EAE mice
in finding the hidden platform during the MWM test. The
protective effects of the KD in this paradigm were sustained at 25–
35 days post EAE induction (Figure 2C). Additionally, motor
activity as monitored by swim speed was affected by changes in
motor disability in EAE mice; naı ¨ve mice swam significantly faster
than SD-fed EAE and KD-fed EAE mice on day 5 of the trial. In
naı ¨ve, KD-fed EAE and SD-fed EAE mice, the speed scores
(2363.2, 3465.8 and 3766.8 cm/sec, respectively) were mea-
sured at 17 days after EAE induction. Intriguingly, recovery of
speed was seen when EAE mice were kept on the KD; no
difference between naı ¨ve and KD-fed EAE mice was found at 25
days of EAE induction (2064.5 vs 2465.6 cm/sec, respectively).
Consistent with this, there was a significant increase in the
latencies of SD-fed EAE mice to finding the hidden platform as
compared to the SD-fed naı ¨ve mice or KD-fed EAE mice
(p,0.01).
Based on these findings, we examined the changes in synaptic
plasticity in EAE mice with SD or KD treatment by measuring
CA1 hippocampal LTP at two different time-points (14–19 days vs.
30–35 days). Measuring LTP is the optimal way to evaluate
memory function in the EAE model due to motor disability and
the possibility of optic neuritis which would preclude accurate
behavioral assessments [21,22]. SD-fed naı ¨ve mice exhibited intact
LTP induction and maintenance at both stages (Figure 2 D, E);
the EPSP amplitude measured 14769% and 14665% at 60 min
post-HFS or TBS, respectively. In SD-fed EAE mice at 60 min
post-HFS or TBS, despite the slightly increased EPSP amplitude at
Figure 1. Changes in EAE mice prior to motor disability. (A)
Assessment of spatial learning and memory using the Morris Water
Maze (MWM) test. Naı ¨ve mice exhibited improved latencies to solve the
maze during the consecutive 5-day trials, but EAE mice did not show
any improvement in spatial learning and memory. (B) In vivo
measurement of reactive oxygen species (ROS) after immunization.
No change in ROS signal was found in naı ¨ve mice, but the progressive
increases in superoxide production were seen 6–10 days post
immunization. (C) No brain structural changes are seen in the early
stage of immunization. All experiments were conducted in groups of
mice (n=4–8) between 6–10 days post immunization before gross
motor deficits were observed.
doi:10.1371/journal.pone.0035476.g001
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significantly different from those seen in both SD-fed naı ¨ve and
KD-fed EAE mice (Figure 2 D, E). In contrast, LTP was fully
restored in KD-fed EAE mice at both stages. Values were not
significantly different compared to those obtained from SD-fed
naı ¨ve mice (p,0.05).
The Ketogenic Diet Reverses Structural Brain Lesions in
EAE Mice
To investigate whether the functional impairments noted above
are associated with changes in lesion size in brains of EAE mice,
we employed high-field animal MR imaging to assess EAE mice
fed either the SD or the KD. Notably, our findings were similar to
clinical data demonstrating periventricular lesions and hippocam-
pal atrophy seen in patients with MS-induced cognitive/memory
decline [3,23]. We found that the periventricular region exhibited
areas of abnormal signal intensity at the peak stage of motor
disability post EAE immunization as compared to naı ¨ve mice
(Figure 3A). In contrast, KD-fed EAE mice showed significantly
reduced lesion signal intensity compared to SD-fed EAE mice.
While we were not able to find any hippocampal structural
changes at 15 days post immunization, T2-weighted imaging
detected hippocampal volume loss at 30 days post immunization.
Importantly, KD-fed EAE mice did not show any hippocampal
volume loss, consistent with our behavioral and electrophysiolog-
ical data, and no significant differences in hippocampal volume
were found between naı ¨ve mice and KD-fed EAE mice
(Figure 3B).
The Ketogenic Diet Diminishes CNS Inflammation and
Oxidative Stress in EAE Mice
Given both functional and structural protective effects of the
KD in our EAE model, we next asked if these beneficial changes
were a consequence of modulating T cell-mediated inflammatory
responses. KD-fed mice had a 2–2.5 fold reduction in CNS-
derived CD4
+ cells and CD11b
+CD45
+ cells (macrophage and
microglia), compared to SD-fed mice (Figure 4A, B). Consistent
with the potential therapeutic role of regulatory T (Treg) cells
against various autoimmune diseases [24], KD treatment in EAE
mice resulted in a tendency toward increased CD4
+CD25
+Foxp3
+
Treg cells (Figure 4C). As shown in Fig 4D, KD-fed mice also
exhibited down-regulation of CD4
+ cells with a statistically
significant matched reduction in the expression levels of cytokines
(IL-1b, IL-6, TNF-a, IL-12, IL-17) and chemokines (IFN-c, MCP-
1, MIP-1a, MIP-1b), compared with SD-fed EAE mice in the
periphery and in the brain (Table 1).
To clarify the functional relationship between ROS generation
and memory dysfunction, we directly measured changes in in vivo
brain ROS levels after intraperitoneal DHE injection. Consistent
with our initial finding of increased ROS production in the early
period following EAE induction (Figure 1), a significant increase
in superoxide radical levels were seen in the brains of SD-fed EAE
mice at the peak stage of motor disability, as compared to levels
observed in SD-fed naı ¨ve mice and KD-fed EAE mice. As
expected, KD treatment strongly suppressed ROS levels in EAE
brains, but the ROS intensity was significantly different from that
seen SD-fed naı ¨ve mice (p,0.01) (Figure 4E).
Figure 2. Effects of the ketogenic diet on motor disability and memory deficit in EAE mice. (A) Starting from day 17 post immunization
(p.i.), KD-fed EAE mice (n=11) showed significantly less motor disability than SD-fed EAE mice (**, p,0.01, Mann-Whitney U test). In KD- fed and SD-
fed EAE mice, the mean clinical scores (1.960.20 vs 2.760.35 and 0.4360.12 vs 1.060.15) were measured at 17 days and 25 days p.i., respectively. (B,
C) Restoration of spatial learning and memory by the KD in EAE mice. MWM testing was conducted in groups of EAE mice either prior to the
occurrence of motor deficits (before 10 days p.i., left panel, B) or from 30 days to 35 days p.i. (right panel, C). The graph illustrates average latencies to
finding the submerged escape platform. Each group consisted of 5–8 mice. Values represent mean6SEM. One way ANOVA followed by Tukey test.
(D) Change in the synaptic plasticity at 13–16 days p.i. with or without the KD. EAE mice exerted impairment in LTP after high-frequency stimulation
(10 slices form 5 mice). Both the naı ¨ve and KD-fed EAE mice demonstrated intact LTP induction and maintenance (9 slices from 4 mice). (E) Change in
synaptic plasticity at 25–35 days p.i. with or without the KD. Neither the naı ¨ve nor KD-fed EAE mice showed changes in LTP maintenance (10 slices
from 5 mice). The dotted line indicates the baseline field potential amplitude. Synaptic plasticity seen during peak and mild stages of motor disability
are depicted in the left and right panels, respectively.
doi:10.1371/journal.pone.0035476.g002
Ketogenic Diet Preserves Memory Dysfunction in EAE
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e35476Discussion
The principal findings of the present study are: (1) both brain
inflammation and oxidative stress are associated with disruption of
memory consolidation in the EAE model of MS; (2) memory
dysfunction in EAE appears independent of structural brain
changes prior to the onset of motor disability (as detected with
high-field MR imaging); (3) at the onset of EAE, impairment of
synaptic plasticity and spatial learning/memory are coincident
with both motor disability and the appearance of brain lesions; (4)
the KD exerts strong suppressive effects on EAE-induced motor
and memory dysfunction, but does not prevent initial EAE onset;
Figure 3. Structural brain changes in EAE mice with and
without KD treatment. (A) T2-weighted images were obtained with
a 7T MR scanner during the peak stage of motor disability. EAE mice
showed abnormal signal intensities adjacent to the lateral ventricles.
Arrows indicate focal lesions on T2-weighted imaging. In contrast,
lesion volumes were significantly reduced in KD-fed EAE mice (N=4–8).
(B) In contrast to the observed hippocampal volume loss in EAE mice at
30 days post immunization, neither naı ¨ve mice nor KD-fed EAE mice
showed changes in hippocampal volume.
doi:10.1371/journal.pone.0035476.g003
Figure 4. The KD ameliorates EAE-mediated CNS-inflammation
and oxidative stress. Comparison of the frequencies of (A) CD4
+/
CD8
+ T cells, (B) CD11b
+/CD45
+ cells on gated lymphocyte populations
in EAE with and without KD treatment. (C) Frequencies of CD4
+CD25
+
Foxp3
+ regulatory T cells. The KD suppressed CNS cellular infiltration
and myelin-reactive T cell responses in EAE. Groups of mice (receiving
standard diet [SD] and KD diet) were immunized with MOG/CFA/PT, and
sacrificed between day 16–19 p.i. Lymph node, spleen and CNS cells
were isolated. (D) Lymphoid (LN) or CNS cells were re-stimulated with
MOG35–55 peptide overnight and IFN-c- and IL-17-expressing CD4
+ T
cells were measured by intracellular staining. The number seen in the
box indicated the average percentage of individual markers on the cells.
(E) Summary data of the percentage of individual marker in the cells (LN
vs. CNS) in SD-treated EAE mice or KD-treated EAE mice. Data are
representative of two independent experiments (n=4–8/group). P
values, Student’s t-test; *, p,0.05. (E) Visualization and quantification of
brain inflammation by in vivo bioluminescence imaging. This is
achieved by imaging reactive oxygen species (ROS) levels in the brain.
Bioluminescent images in live mice were captured during a 1 min
acquisition time using the Xenogen IVIS system at several time points
after injection of 27 mg/kg dihydroethidium. Representative images of
ROS seen in the left panel were captured in naı ¨ve mice and EAE mice
with and without KD treatment. All experiments were conducted on
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a reduction in lymphocyte proliferation, cytokine/chemokine
expression and oxidative stress.
There is mounting evidence that an aberrant cytokine and
chemokine burst characterized by T-cell proliferation may be
a critical factor in the initiation of MS/EAE [7,8]. Although
memory impairment has been shown to result from increased
cytokine expression (e.g., IL-1b, IL-6 and TNF-a) in patients with
Alzheimer’s disease, vascular dementia and post-operatively
[25,26], the functional role of inflammatory mediators in MS/
EAE-mediated memory impairment has yet to be fully elucidated.
Our findings strongly suggest that CNS inflammation plays a major
role in the memory impairment seen in EAE. Furthermore, the
broad modulation of inflammatory cytokines and chemokines by
the KD appears linked to the diet-induced attenuation of adverse
functional and structural consequences in EAE. We found that
KD treatment increased the differentiation of Treg cells and led to
a concomitant decrease in IL-6 and Th17 cell generation in EAE,
changes that are consistent with a recent study reporting similar
findings in MS, and proposed to yield beneficial effects [27].
Collectively, our data strongly support the notion that the KD may
be clinically useful in patients with MS.
It is well known that up-regulated cytokine/chemokine
expression triggers reactive oxygen species (ROS) production,
which subsequently promotes an inflammatory cascade in
a feedback manner [10,28]. The link between neuroinflammation
and pathologic ROS production is further supported by a prior
study demonstrating elevations in thiobarbituric acid substances
and F2-isoprostane levels (both indicators of oxidative stress) in the
cerebrospinal fluid of MS patients [29]. Additionally, ROS
generated by microglia and macrophage activation has been
correlated with demyelination and axonal injury in both EAE and
MS [10,30,31].
Consistent with these studies, our data clearly indicates that
in vivo ROS generation is associated with impaired memory
consolidation post EAE induction. The KD not only significantly
reduces CNS-derived CD4
+ cells and CD11b
+CD45
+ cells, but
also restores memory function in EAE mice possibly by reducing
in vivo brain ROS levels. While this protective effect may be
a consequence of decreased microglia and macrophage activation,
we cannot exclude the possibility that the KD enhances intrinsic
antioxidant capacity. Earlier studies have shown elevations in
hippocampal glutathione peroxidase activity and catalase levels
induced by the KD and its associated metabolites such as ketone
bodies [32,33].
MR imaging studies have helped solidify the concept that the
memory impairment seen in MS patients is closely related to
structural brain changes [3,4]. Notably, the CA1 hippocampal
region in humans becomes atrophic in the early stages of MS
which then spreads to adjacent areas [34]. This clinical
observation is paralleled by a recent study demonstrating loss of
neurons, synaptic integrity and memory impairment in EAE mice
[5]. In the present study, hippocampal volume loss in EAE mice
was also documented on MR imaging at the same time when
impairment of memory consolidation was observed.
Many metabolic substrates [e.g., polyunsaturated fatty acids
(PUFAs) and ketones] and hormones [e.g., leptin and adiponectin]
[35–37] are both elaborated and altered by KD treatment.
Interestingly, dietary supplementation with omega-3 PUFAs –
which mirrors one important facet of the KD – led to decreased
pro-inflammatory and enhanced anti-inflammatory changes in
models of MS [38]. However, whether PUFAs are beneficial in
MS patients remains controversial [39–42].
There are other metabolic players that may be relevant to EAE.
It is well known that both adiponectin increases and leptin
decreases after chronic calorie restriction. Thus, it is of interest
that calorie restriction – which shares some metabolic features
with the KD – exerted anti-inflammatory and neuroprotective
effects in EAE [43]. Prior studies have demonstrated that up-
regulation of adiponectin suppressed inflammatory mediators (e.g.,
TNF-a, IL-1, IL-6, and IL-10) and led to weight loss [44], whereas
increased leptin expression correlated with a pro-inflammatory
action [45]. Additionally, KD-treated obese rats showed increases
in adiponectin expression, weight-loss and down-regulation of
TNF-a levels [37]. Thus, it appears that a metabolic treatment
such as the KD or calorie restriction induces changes in specific
hormones that positively modulate neuroinflammation.
Another potential pathogenic mechanism in MS is hypoxia-
induced mitochondrial dysfunction in excitable demyelinated
axons, which leads to decreased ATP production [46]. Further-
more, down-regulation of mitochondrial uncoupling protein
(UCP) activity in EAE –which results in pro-inflammation and
ROS generation – was shown to induce serious motor disability
[47]. In this light, it is interesting to note that the KD has been
shown to provide synaptic protective effects in hippocampal slices
under conditions of low glucose-induced metabolic stress, and was
correlated with up-regulation of genes encoding mitochondrial
ATP synthases [48]. Similarly, a more recent study demonstrated
that ketone bodies alone afforded synaptic protection against the
effects of mitochondrial respiratory chain inhibitors via enhanced
ATP generation and antioxidant activity [33]. Further, it has been
shown that the KD increases the expression and activity of UCPs
groups of mice (n=4–8) between days 14–19 p.i. Data are represen-
tative of two independent experiments (mean and SEM). P values, one
way ANOVA; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0035476.g004
Table 1. Inflammatory mediators assayed in EAE mice.
Cytokine/chemokine IL-1 b IL-6 TNF-a IL-12 IL-17A IFN-c TGF-b MCP-1 MIP-1a MIP-1b
CNS EAE 33.365.8 211636.5 50.2611.3 18.263.8 131622.3 75.6611.9 116626.0 42.666.1 666680.8 200.6646.3
EAE+KD 11.563.8* 50.668.7** 25.265.1* 12.262.1* 40.164.3** 23.963.3* 90.4619.1 15.762.6* 226650.8** 110.1621.3*
Periphery EAE 50.369.3 99.2611.8 37.665.8 11.861.9 152615.4 27.166.0 179620.9 56.368.9 1061695.9 353636.4
EAE+KD 22.564.7* 57.664.7* 20.763.7* 6.2460.7* 70.9611.0* 20.165.6 175611.1 33.967.5* 7896106.3* 216630.0*
Lymph node and CNS homogenates were prepared from mice in the indicated groups at day 15 p.i. Cytokine concentrations were measured by a Multi-Analyte
ELISArray Kit (SA Biosciences, MD). Unit: pg/ml; n=4/group. P values, student’s t-test or Wilcoxon test;
**, p,0.01;
*, p,0.05.
doi:10.1371/journal.pone.0035476.t001
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ROS generation [19]. Taken together, the experimental evidence
would strongly suggest that bioenergetic stabilization and sub-
sequent reduction in oxidative stress may yield neuroprotective
effects in MS/EAE.
In summary, we have shown that memory deficits in EAE mice
are correlated with brain inflammation as evidenced by the
enhanced expression of inflammatory cytokines and chemokines.
And importantly, the KD significantly attenuated brain inflam-
mation and reversed both memory dysfunction and motor
impairment in EAE mice. There is mounting evidence that
metabolic substrates (and certain hormones) can reduce in-
flammatory responses, and as a consequence provide both
structural and functional neuroprotective effects. Since the KD is
currently available in many clinical centers throughout the world,
patients with MS may readily benefit from this non-pharmaco-
logical treatment option. In light of the present study and
supportive evidence from the literature noted above, prospective,
controlled clinical trials assessing the therapeutic effects of the KD
now appear warranted.
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